

Elos Medtech – Sustainability Report 2018 published

The English version of Elos Medtech Sustainability Report 2018 have today been published on our web site elosmedtech.com/who-we-are/sustainability/

In the report, Elos Medtech highlights the year's most important initiatives in connection with the publication of its Sustainability Report in 2018. To contribute to a more sustainable environment, the reader is primarily referred to the online version of the Sustainability Report as well as the Annual Report 2018. In doing so, we have made a significant reduction to the number of printed copies of the reports.

Summary of Elos Medtech's sustainability work in 2018:

- Reduced consumption of energy from non-renewable resources compared to 2017
- 7 percent of the total investments (the target was at least 5 percent) was categorized as sustainable investments, i.e. investments that have a direct impact on our ecological footprint
- Reduced scrap cost by more 20 percent compared to 2017
- Roll out of the new Code of Conduct through local training sessions to all employees

Elos Medtech is one of the leading development and production partners for medical technology products and components in the world, with focus on dental and orthopedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and the US. Customers are medical technology companies operating internationally.

Elos Medtech employs more than 550 people worldwide and generates revenue that exceeds MSEK 600. Elos Medtech has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list.

Göteborg, April 4, 2019

Elos Medtech AB (publ)

For further information, please contact:

Jan Wahlström, CEO, +46 70 212 18 89, jan.wahlstrom@elosmedtech.com or

Malin Gustavsson, Marketing Director +46 70 359 80 60,
malin.gustavsson@elosmedtech.com

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

This information is information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on April 4, 2019, at 17:30 (CET).